The text starts here.

News Release

September 12, 2003

Eisai Launches MAXALT (R) 10 mg Tablet, MAXALT RPD (R) 10 mg Tablet ,
5-HT1B/1D Receptor Agonist-Type Migraine Treatment Agents

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced the launch of MAXALT (R) 10 mg Tablet and MAXALT RPD*(R)10 mg Tablet (generic name: rizatriptan benzoate) on September 24, following the completion of the national health insurance price listing as of today.

MAXALT (R) 10mg Tablet is a new triptan-type migraine treatment agent which acts selectively on 5-HT (serotonin) 1B/1D receptors, which was developed by Merck & Co., Inc. MAXALT (R) 10mg Tablet improves headache pain quickly by suppressing vascular inflammation through constriction of the blood vessels that expand when symptoms of migraine develop, and it demonstrated superior rates of complete resolution of migraines as compared to placebo. MAXALT (R) 10mg Tablet also improves the uncomfortable symptoms that accompany migraines such as nausea, vomiting, or hypersensitivity to light or sound.
In addition to MAXALT (R) 10 mg Tablet, Eisai is launching MAXALT RPD (R) 10mg Tablet (Rapid disintegration tablet) which can be administered without water. This formulation was developed to increase patient's convenience in administration.

MAXALT (R) 10mg has been approved in 78 countries around the world (as of December 2002), and launched worldwide including in the U.S. and Europe. In Japan, Kyorin Pharmaceutical Co., Ltd. imports the product with import approval from Merck & Co., Inc. and Eisai distributes the agent.

Eisai targets 1 billion yen of sales in the first year of launch in fiscal 2003, and 10 billion yen of peak yearly sales. Eisai aims to become the top brand in the Japanese market for migraine treatment agents, and increase its presence in the field of neurology, which is a focused disease area of the Company.

[The product outline and explanations of terms are attached below for reference]

[Product Outline of MAXALT (R) 10mg Tablet, MAXALT RPD*(R)10mg Tablet]
Product Name:   MAXALT (R)10mg Tablet, MAXALT RPD*(R)10mg Tablet (* Rapid disintegration)
(dangerous drug, designated drug, prescription required drug)
Generic Name: rizatriptan benzoate
Active Ingredient:
MAXALT (R)10mg Tablet rizatriptan benzoate 14.53 mg
(rizatriptan 10mg)
MAXALT RPD*(R)10mg Tablet rizatriptan benzoate 14.53 mg
(rizatriptan 10mg)
Indication: Migraine
Dosage and Administration: Routinely, for an adult, 10mg per once of rizatriptan should be orally administered when symptom of migraine developed. When no response to the first dose, a second dose may be taken anytime after two hours of administrating the first dose. Dosage in a day is limited up to 20 mg.
MAXALT (R)10mg Tablet

1089.30 yen
MAXALT RPD*(R)10mg Tablet 1089.30 yen
MAXALT (R)10mg Tablet

6 tablets (PTP6T1)
18 tablets (PTP6T3)
MAXALT RPD*(R)10mg Tablet 6 tablets (3 tablets case2)
18 tablets (3 tablets case6)
Import Approval Date: July 17, 2003
Listed date in the national health insurance list in Japan: September 12, 2003
Projected launched date: September 24, 2003
Importer: Kyorin Pharmaceutical Co., Ltd.
Distributor: Eisai Co., Ltd.

[Explanation of Terms]
A throbbing headache that occurs repeatedly and episodically, often appearing unilaterally. The headache occurs one or several times in a month, and lasts from a few hours to several days. Onset may be preceded by sensory disorders such as scintillating scotoma, and is often accompanied by nausea, vomiting, or hypersensitivity to light or sound. The cause of migraine headaches has not yet been definitively determined, but it is recognized that the trigeminal nerve or dilation of the cerebral blood vessels are involved with the onset of migraine headaches.
The prevalence rate of migraines in Japanese aged 15 years and older including suspected cases was reported as 8.4% (male: 3.6%, female: 13.0%). Approximately 8.4 million people are estimated to have experienced migraine in Japan. (Sakai F; Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 1997; 17: 15 - 22)
2.5-HT1B/1D receptor agonist-type migraine treatment agent
5-HT (serotonin) 1B/1D receptor agonist acts selectively on 5-HT (serotonin) 1B/1D receptors, constricting the blood vessels that expanded when symptoms of migraine develop, and controlling vascular inflammation, through suppressing secretion of neuropeptid which is involved to the blood vessels expansion.